BACKGROUND: Arteriovenous fistula (AVF) is the most preferred vascular access for hemodialysis patients, and early failure of AVF is one of the most avoidable complications of this procedure. We retrospectively evaluated whether adjuvant systemic heparinization just before arterial manipulation could reduce early failure of primary AVF. METHODS: Three hundred and fifty-six patients with end-stage renal failure who underwent primary AVF surgery from April 2009 to September 2020 were enrolled in this study. The patients were divided into two groups based on whether they received adjuvant heparinization or not. Patient backgrounds, frequency of early AVF failure, and bleeding events were compared between the two groups. Multivariate Cox regression analysis identified risk factors for early AVF failure. RESULTS: Early failure of AVF was observed in only 2 of 157 patients (1.2%) in the adjuvant group, and the incident was significantly lower than observed in the non-adjuvant group, i.e., 17 of 199 patients (8.5%) (p = 0.002). Bleeding events were not significantly different between the two groups. Seven of 157 patients (4.5%) in the adjuvant group and 7 of 199 patients (3.5%) in the non-adjuvant group experienced bleeding events (p = 0.785). Female sex, use of steroids, hypoalbuminemia, venous stenosis in pre-surgical evaluation, arterial spasm in the perioperative period, new-onset venous stenosis after AVF anastomosis, technical failure of surgery, no early cannulation after surgery, and non-adjuvant heparinization were related to early AVF failure in the multivariate regression analysis. CONCLUSION: Adjuvant systemic heparinization therapy just before arterial manipulation reduced early failure of primary AVF without increasing bleeding events.
BACKGROUND: Arteriovenous fistula (AVF) is the most preferred vascular access for hemodialysis patients, and early failure of AVF is one of the most avoidable complications of this procedure. We retrospectively evaluated whether adjuvant systemic heparinization just before arterial manipulation could reduce early failure of primary AVF. METHODS: Three hundred and fifty-six patients with end-stage renal failure who underwent primary AVF surgery from April 2009 to September 2020 were enrolled in this study. The patients were divided into two groups based on whether they received adjuvant heparinization or not. Patient backgrounds, frequency of early AVF failure, and bleeding events were compared between the two groups. Multivariate Cox regression analysis identified risk factors for early AVF failure. RESULTS: Early failure of AVF was observed in only 2 of 157 patients (1.2%) in the adjuvant group, and the incident was significantly lower than observed in the non-adjuvant group, i.e., 17 of 199 patients (8.5%) (p = 0.002). Bleeding events were not significantly different between the two groups. Seven of 157 patients (4.5%) in the adjuvant group and 7 of 199 patients (3.5%) in the non-adjuvant group experienced bleeding events (p = 0.785). Female sex, use of steroids, hypoalbuminemia, venous stenosis in pre-surgical evaluation, arterial spasm in the perioperative period, new-onset venous stenosis after AVF anastomosis, technical failure of surgery, no early cannulation after surgery, and non-adjuvant heparinization were related to early AVF failure in the multivariate regression analysis. CONCLUSION: Adjuvant systemic heparinization therapy just before arterial manipulation reduced early failure of primary AVF without increasing bleeding events.
Authors: Maurizio Gallieni; Markus Hollenbeck; Nicholas Inston; Mick Kumwenda; Steve Powell; Jan Tordoir; Julien Al Shakarchi; Paul Berger; Davide Bolignano; Deirdre Cassidy; Tze Yuan Chan; Annemieke Dhondt; Christiane Drechsler; Tevfik Ecder; Pietro Finocchiaro; Maria Haller; Jennifer Hanko; Sam Heye; Jose Ibeas; Tamara Jemcov; Stephanie Kershaw; Aurangzaib Khawaja; Laura Labriola; Carlo Lomonte; Marko Malovrh; Anna Marti I Monros; Shona Matthew; Damian McGrogan; Torsten Meyer; Sotirios Mikros; Ionut Nistor; Nils Planken; Ramon Roca-Tey; Rose Ross; Max Troxler; Sabine van der Veer; Raymond Vanholder; Frank Vermassen; Gunilla Welander; Teun Wilmink; Muguet Koobasi; Jonathan Fox; Wim Van Biesen; Evi Nagler Journal: Nephrol Dial Transplant Date: 2019-06-01 Impact factor: 5.992
Authors: Alik Farber; Peter B Imrey; Thomas S Huber; James M Kaufman; Larry W Kraiss; Brett Larive; Liang Li; Harold I Feldman Journal: J Vasc Surg Date: 2016-01 Impact factor: 4.268
Authors: Bonnie R Wang; Vincent L Rowe; Sung Wan Ham; Sukgu Han; Kaushal Patel; Fred A Weaver; Karen Woo Journal: Am Surg Date: 2010-10 Impact factor: 0.688
Authors: George E Smith; Panos Souroullos; Thomas Cayton; Amy Harwood; Daniel Carradice; Ian C Chetter Journal: J Vasc Access Date: 2015-12-07 Impact factor: 2.283
Authors: Marcus D'Ayala; Robina M Smith; Catherine Martone; William Briggs; Jonathan S Deitch; Leslie Wise Journal: Ann Vasc Surg Date: 2007-12-04 Impact factor: 1.466